Chris Ryan

IMM2510 plus chemotherapy generated responses in the first-line treatment of advanced non–small cell lung cancer.

The FDA has granted fast track designation to ateganosine for non–small cell lung cancer.

DZD8586 was active with a tolerable safety profile in heavily pretreated, relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Results of an observational study showed that immunohistochemistry could act as a biomarker for the early detection of TP53‐mutant MDS or AML.

The EMA’s CHMP recommended the approval of vimseltinib for symptomatic tenosynovial giant cell tumor.

Perioperative tislelizumab received a positive CHMP opinion for resectable non–small cell lung cancer at high risk of recurrence.

The combination of sonrotoclax and zanubrutinib produced deep and durable responses in relapsed/refractory mantle cell lymphoma.

The FDA has approved a generic version of ibrutinib tablets for B-cell malignancies.

The FDA has granted breakthrough therapy designation to elironrasib for KRAS G12C–mutated advanced NSCLC previously treated with chemotherapy and immunotherapy.

The novel bispecific antibody TQB2930 plus chemotherapy elicited responses in heavily pretreated HER2-positive breast cancer.

The combination of talazoparib and tazemetostat was safe and led to PSA reductions in certain patients with metastatic castration-resistant prostate cancer.

The FDA granted fast track designation to DB-1310 for patients with pretreated, advanced non–small cell lung cancer harboring select EGFR mutations.

The FDA has issued a complete response letter for RP1 plus nivolumab for advanced melanoma after a PD-1 inhibitor–containing regimen.

The European Commission approved obe-cel for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

Osimertinib plus chemotherapy improved overall survival in the first-line treatment of advanced non–small cell lung cancer harboring EGFR mutations.

JSKN003 demonstrated tolerability and antitumor activity in heavily pretreated HER2-positive breast cancer.

The FDA issued a CRL to the application for glofitamab plus chemotherapy in relapsed/refractory diffuse large B-cell lymphoma.

The FDA granted breakthrough therapy designation to first-line trastuzumab deruxtecan plus pertuzumab in HER2-positive metastatic breast cancer.

Justin T. Jordan, MD, MPH, FAAN, discusses the implications of the FDA approval of mirdametinib for adult NF1-associated plexiform neurofibromas.

Safety and efficacy data for elotuzumab support its further investigation in the treatment of myelofibrosis.

Certain factors were associated with sustained remission with obe-cel in acute lymphoblastic leukemia.

The FDA received a BLA resubmission for tabelecleucel in EBV-positive post-transplant lymphoproliferative disease.

Pasritamig was safe and produced durable responses in heavily pretreated metastatic castration-resistant prostate cancer.

Adjuvant dalpiciclib plus endocrine therapy met the iDFS primary end point in the DAWNA-A trial in HR-positive, HER2-negative early breast cancer.

Bexobrutideg received European Medicines Agency orphan drug designation for Waldenström macroglobulinemia.

Bria-IMT plus checkpoint inhibition displayed a potential overall survival benefit in heavily pretreated, hormone receptor–positive breast cancer.

The FDA granted orphan drug designation to MB-101 for recurrent diffuse and anaplastic astrocytoma and glioblastoma.

The EHA-EMN guidelines now include melphalan flufenamide for certain patients with relapsed/refractory multiple myeloma.

Bezuclastinib improved total symptom score vs placebo in non-advanced systemic mastocytosis, meeting the primary end point of the SUMMIT trial.

European approval is being sought for the combination of niraparib, abiraterone acetate, and prednisone or prednisolone for HRR-mutated mHSPC.